Tag: Joseph Eron

William A. Fischer II, MD, Director of Emerging Pathogens at UNC’s Institute for Global Health and Infectious Diseases and Joe Eron, MD, UNC Chief of Infectious Diseases and chair of the ACTG, co-authored a study that found tecovirimat used to treat mpox does not shorten time to lesion resolution, reduce...

A trial led by Joe Eron, MD, a researcher with the UNC Institute for Global Health and Infectious Diseases, marks a significant milestone toward what could become the first complete long‑acting HIV regimen requiring dosing only twice per year. This new report is considered the first Phase 2 study to...

Chapel Hill, N.C. — A Phase 2 study led by Dr. Joe Eron, a member of the UNC Institute for Global Health and Infectious Diseases, shows an investigational once‑weekly, all‑oral combination of islatravir (ISL) and lenacapavir(LEN) maintains high levels of virologic suppression through 48 weeks in adults living with HIV....

In a commentary published by Nature Medicine, Dr. Myron Cohen and Dr. Joe Eron, leaders of the UNC Institute for Global Health and Infectious Diseases, identify numerous medical advances originating from U.S. federally funded HIV research. They say the future of HIV research and the U.S.’s scientific leadership depends on...

The National Institutes of Health held a congressional briefing July 9 at the Dirksen Senate Office Building in Washington, DC. Dr. Myron Cohen, director of the Institute for Global Health and Infectious Diseases, and Dr. Joe Eron, chief of infectious diseases, kicked off the briefing session with an overview of HIV...

There’s a new tool to help prevent HIV in people who are at risk of contracting the virus, and health experts say it has the potential to change the trajectory of the global epidemic and may be especially beneficial for some older adults. In June, the U.S. Food and Drug...

Hospitalization causes among persons with HIV (PWH) have shifted to non-AIDS conditions, but the complete disease profile of hospitalized PWH has not been well described. To inform hospitalization and readmission prevention efforts, Thibaut Davy-Mendez, PhD, MSPH, Sonia Napravnik, PhD, and Joseph J. Eron, MD, examined non-AIDS disease prevalence among PWH hospitalized in 4...

As HIV care improves, people with Aids are now hospitalized more for non-AIDS conditions.  Despite this, the complete disease profile of hospitalized people with HIV has not been well described. To inform hospitalization and readmission prevention efforts, researchers with the institute examined non-AIDS disease prevalence among PWH hospitalized in 4...

The ACTG (Advancing Clinical Therapeutics Globally, formerly the AIDS Clinical Trials Group) Network celebrates the A5321 trial, and a successful ten-year milestone this month. Joe Eron, MD, Chief of Infectious Diseases, is the ACTG Chair and leader of the ACTG Executive Committee. “The A5321 has been ongoing for 10 years...

Investigators with the Institute for Global Health and Infectious Diseases (IGHID) participated in the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, California, March 9-12. Following are some highlights.   In a CROI preview, Joe Eron, MD, was interviewed for the “Going Anti-Viral” IAS-USA podcast, discussing the...

In an interview with Dr. Michael Saag for the “Going Anti-Viral Podcast” posted March 7, Dr. Joe Eron described his presentation for the Conference on Retroviruses and Opportunistic Infections CROI (2025). The two discuss the state of HIV cure research, recognizing why it has been difficult to develop a cure...

The ID Fellowship Program led by Christopher Sellers, MD, MPH, held a reception for six graduating fellows at the Siena Hotel in Chapel Hill, on the evening of June 18. Joined by Joe Eron, MD, chief of the division of infectious diseases, Myron Cohen, MD, director of the Institute for...